Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 1Phase 1 1

Status

Completed 3Terminated 2

Sponsor Class

OTHER 92NIH 15NETWORK 5INDUSTRY 3

Study Type

Interventional 5

Sponsor

Cancer Type

Lymphoid 39Other hematologic neoplasm 25Sarcoma 23CNS 23Gynecologic 14Genitourinary 12Breast 9Thoracic 5Plasma cell 5Gastrointestinal 3Endocrine 3Dermatologic 3Myeloid 2Head & Neck 2Classical hematology 2Other solid neoplasm 1

Conditions

Multiple Myeloma 5Immunoglobulin Light-chain Amyloidosis 3Neoplasms, Plasma Cell 2Drug-Related Side Effects and Adverse Reactions 1

Interventions

Dexamethasone 48Bortezomib 22Lenalidomide 20Cyclophosphamide 20daratumumab 18Calcium Dobesilate 15Melphalan 13Thalidomide 12carfilzomib 9pomalidomide 7Prednisone 7dexamethasone acetate 6dexamethasone 21-phosphate 6auricularum 6Peripheral Blood Stem Cell Transplantation 6Doxorubicin 6isatuximab 5Filgrastim 5Vincristine 4Interferon-alpha 3Etoposide 3selinexor 2sargramostim 2ixazomib 2elotuzumab 2cobimetinib 2belantamab mafodotin 2Steroids 2Stem Cell Transplantation 2Radiotherapy 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
NETWORK × Filgrastim × Plasma cell × Clear all
NCT00003353 2023-06-22

High-Dose Melphalan Plus Peripheral Stem Cell Transplantation in Treating Patients With Primary Systemic Amyloidosis

Eastern Cooperative Oncology Group

Phase 2 Completed
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Multiple Myeloma, Neoplasms, Plasma Cell

NCT00052884 2023-06-18

Amifostine and Melphalan in Treating Patients With Primary Systemic Amyloidosis Who Are Undergoing Peripheral Stem Cell Transplantation

Eastern Cooperative Oncology Group

Phase 1 Terminated
8 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Multiple Myeloma, Neoplasms, Plasma Cell, Drug-Related Side Effects and Adverse Reactions

NCT00064337 2018-08-09

S0115, High-Dose Melphalan and Autologous Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Primary Systemic Amyloidosis

SWOG Cancer Research Network

Phase 2 Completed
104 enrolled 6 charts
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Multiple Myeloma

NCT00040937 2016-12-08

S0204 Thalidomide, Chemotherapy, and Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma

SWOG Cancer Research Network

Phase 2 Completed
147 enrolled 6 charts
Plasma cell

Multiple Myeloma

NCT00005834 2015-03-06

S9922 Combination Chemo Plus Filgrastim With or Without Thalidomide in Refractory Multiple Myeloma

SWOG Cancer Research Network

Phase 3 Terminated
19 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡